Effects of Barasertib-hQPA on Drug Resistance in Acute Myeloid Leukaemia
Author Information
Author(s): P. G. Martin, C. Seedhouse, N. H. Russell, M. Pallis
Primary Institution: The University of Nottingham
Hypothesis
Does the Aurora-B kinase inhibitor barasertib-hQPA affect the sensitivity of acute myeloid leukaemia cells expressing P-glycoprotein and BCRP?
Conclusion
P-glycoprotein and BCRP status in acute myeloid leukaemia patients should be monitored to assess their impact on the effectiveness of barasertib-hQPA treatment.
Supporting Evidence
- Pgp and BCRP positive primary samples were less sensitive to barasertib-hQPA induced pHH3 inhibition.
- IC50 inhibition of pHH3 by barasertib-hQPA was achieved in 94.6% of primary samples after 1 hour drug treatment.
- The study created a new cell line, OCI-AML3DNR, which over-expresses Pgp.
Takeaway
This study looked at how a new cancer drug works on leukaemia cells. It found that some cells are better at pushing the drug out, making it less effective.
Methodology
The study measured the effect of barasertib-hQPA on cell viability and pHH3 biomarker in leukaemic cell lines and primary AML samples using flow cytometry.
Limitations
The study primarily focused on specific cell lines and may not fully represent the diversity of AML.
Participant Demographics
The study included 37 primary AML samples, with 24.3% positive for P-glycoprotein and 25.7% positive for BCRP.
Statistical Information
P-Value
<0.001
Confidence Interval
95%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website